Key Takeaways SRPT is pausing U.S. Elevidys shipments to complete safety labeling changes and respond to FDA requests. The move follows patient deaths linked to ALF in studies using the same AAVrh74 gene therapy vector. SRPT expects significant financial impact in quarters ahead as Elevidys drove over half of its Q1 revenues.Shares of Sarepta Therapeutics (SRPT) are declining in the pre-market hours today after the announcement that it will voluntarily and temporarily halt all U.S. shipments of Elevidys, ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but those who sign up for the yearly plan will be able to take advantage of a 33.50% dis ...

Danaher (DHR) Q2 2025 Earnings Call July 22, 2025 08:00 AM ET Company ParticipantsJohn Bedford - VP - IRRainer Blair - President & CEOMichael Ryskin - Managing DirectorDoug Schenkel - MD - Life Science Tools & DiagnosticsMatt McGrew - EVP & CFOScott Davis - Chairman, CEO & Founding Partner – Multi-Industry ResearchTycho Peterson - Managing Director, Global EquitiesVijay Kumar - Senior MDPuneet Souda - Senior MDConference Call ParticipantsDan Leonard - MD & Research AnalystDaniel Brennan - Senior Equity Rese ...

Danaher (DHR) Q2 2025 Earnings Call July 22, 2025 08:00 AM ET Speaker0My name is Margo, and I'll be your conference facilitator this morning. At this time, I'd like to welcome everyone to Danaher Corporation's Second Quarter twenty twenty five Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I will now turn the call over to John Bedford, Vice President of Investor Relations.Mr. Bedf ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...

SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio’s Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedicat ...

诉讼案件概述 - 针对Capricor Therapeutics公司的证券集体诉讼案件已启动 旨在为2024年10月9日至2025年7月10日期间因涉嫌证券欺诈而遭受损失的投资者追偿损失 [1] - 诉讼涉及公司针对治疗杜氏肌营养不良症(DMD)相关心肌病的主打细胞疗法药物deramiocel的虚假陈述 [2] 指控核心内容 - 公司被指控在向投资者提供关于deramiocel药物生物制品许可申请(BLA)进展的积极陈述时 隐瞒了HOPE-2二期临床试验四年安全性和有效性数据的不利事实 [2] - 2025年7月11日 FDA发布完整回复函(CRL)拒绝BLA申请 理由是缺乏有效性的实质性证据且需要更多临床数据 同时指出化学制造与控制(CMC)部分存在未解决问题 [2] 市场影响 - FDA拒绝决定导致公司股价从2025年7月10日的11.40美元/股暴跌至次日7.64美元/股 单日跌幅达33% [2] 法律程序进展 - 受损投资者需在2025年9月15日前申请成为首席原告 但参与赔偿无需承担首席原告义务 [3] - 集体诉讼成员可能无需支付自付费用即可获得赔偿 [3] 律所背景 - Levi & Korsinsky律所过去20年累计为受损股东追回数亿美元赔偿 拥有70多名专业人员组成的证券诉讼团队 [4] - 连续七年被ISS证券集体诉讼服务评为全美前50大证券诉讼律所 [4]

文章核心观点 Akari Therapeutics公司CEO参与虚拟投资者会议并深入介绍公司情况，公司专注开发新型免疫肿瘤有效载荷抗体药物偶联物用于癌症治疗 [1][2] 公司动态 - 公司CEO Abizer Gaslightwala参加虚拟投资者“你的故事”夏季聚焦按需会议并深入介绍公司情况，会议按需视频网络直播可在相关网站观看 [1][2] 公司概况 - 专注开发新型免疫肿瘤有效载荷抗体药物偶联物治疗癌症 [1][3] 公司产品 - 已开发首款新型有效载荷PH1，是一种剪接体抑制剂，与当前使用拓扑异构酶1抑制剂或微管蛋白抑制剂的ADC有效载荷在作用机制上有显著差异，在临床前动物模型中可诱导癌细胞死亡并激活免疫细胞产生持久活性，公司可基于该有效载荷针对一系列癌症靶点生成多个ADC分子 [3] - 领先候选药物AKTX - 101靶向癌细胞上的Trop2受体并将新型PH1有效载荷直接递送至肿瘤，临床前研究显示其比传统有效载荷的ADC有显著活性和延长生存期效果，还可能与检查点抑制剂产生协同作用，单药和联合使用时都能延长生存期 [3] - 公司正在为新型有效载荷PH1生成验证数据，以推进领先资产及其他未披露靶点的研究 [3] 公司信息 - 公司官网为www.akaritx.com，可在X和LinkedIn上关注 [4] 投资者关系 - 投资者关系联系人是JTC Team, LLC的Jenene Thomas，电话908 - 824 - 0775，邮箱AKTX@jtcir.com [5]

文章核心观点 公司宣布消除与YA II PN, Ltd的可转换票据债务，这加强了资本结构，有利于实现长期目标和推进加密货币业务战略 [1][2] 债务消除情况 - 公司消除了2025年1月16日与YA II PN, Ltd的可转换票据债务，清除了对其的未偿债务义务 [1] 债务消除影响 - 消除未偿债务义务加强了公司资本结构，有助于实现长期目标 [2] - 精简的资本结构有助于公司推进在加密货币领域的战略业务拓展 [2] 公司业务概况 - 公司是生物制药和技术公司，旗下有多个子公司，生物制药部门专注癌症、自身免疫和传染病的细胞疗法平台开发 [3] - 公司治疗产品组合有从Deverra Therapeutics授权的资产，包括同种异体细胞免疫疗法平台和DVX201技术 [4] - 公司正在开发从匹兹堡大学授权的通用多抗原CAR技术，以及与VyGen - Bio和卡罗林斯卡学院合作的GEAR细胞疗法和配套诊断平台 [4] - 公司新成立技术部门，专注通过先进技术提升运营能力，有从NexGenAI Solutions Group收购的人工智能营销软件和机器人流程自动化工具 [5] - 公司总部位于宾夕法尼亚州韦克斯福德，致力于在FDA监管框架内推进使命，确保合规和患者护理标准 [6] 联系方式 - 投资者关系邮箱：IR@coeptistx.com [10]

Ra’anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for ...